Anakinra (Kineret®), an interleukin-1 (IL-1) inhibitor, has been granted a licence for treatment of CAPS in children and adults by the Medicines and Healthcare Products Regulatory Agency (MHRA). Anakinra is the first CAPS treatment licensed for use in children as young as eight months. CAPS is an umbrella term for a number of ultra-rare, life-long, severely debilitating autoinflammatory diseases which cause rash, headache, fever, joint pain and other inflammatory symptoms. CAPS affects approximately 1 in 1,000,000 people in the UK.
More...
More...